The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro

References

• Feyen JHM, van der Wilt G, Moonen P, et al. Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drug. Prostaglandins. 1984;28:213–20.
   Web of Science ®Google Scholar
• Harrison JR, Lorenzo JA, Kawaguchi H, et al. Stimulation of prostaglandin E2 production by interleukin-1a and transforming growth factor a in osteoblastic MC3T3-E1 cells. J Bone Miner Res. 1994;9:817–23.
   PubMed Web of Science ®Google Scholar
• Rodan SB, Rodan GA, Simmons HA, et al. Bone resorptive factor produced by osteosarcoma cells with osteoblastic features is PG E2. Biochem Biophys Res Common. 1981;102:1358–65.
   PubMed Web of Science ®Google Scholar
• Fletcher BS, Kujubu DA, Perrin DM, et al. Structure of the mitogen-inducible TIS10 gene and demonstration that TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338–44.
   PubMed Web of Science ®Google Scholar
• Kujubu DA, Fletcher BS, Vamum BC. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cell, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266: 12866–72.
   Google Scholar
• Vane J. Towards a better aspirin. Nature. 1994;367:215–6.
   PubMed Web of Science ®Google Scholar
• Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991;88: 2692–6.
   PubMed Web of Science ®Google Scholar
• Khanna IK, Weier RM, Yu Y. 1, 2-Diarylimidazoles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem. 1997;40: 1619–33.
   Google Scholar
• Khanna IK, Weier RM, Yu Y, et al. 1, 2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active anti-inflammatory agents. J Med Chem. 1997;40:1634–47.
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxy-genase-2 inhibitors: identification of 415-(4-methylpheny1)-3-trifluoromethy1-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347–65.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shaffer A, Portanova J, et al. Inhibition of cyclooxy-genase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283: 1069–75.
   PubMed Web of Science ®Google Scholar
• Lanza H, Rack MF, Callison DA. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology. 1997;112: 194.
   Google Scholar
• Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastro-intestinal and platelet effects. Arthritis Rheum. 1998;41: 1591–602.
   PubMed Web of Science ®Google Scholar
• Simon LS, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized control trial. JAMA. 1999;282:1921–8.
   PubMed Web of Science ®Google Scholar
• Zhao SZ, Hatoum HT, Hubbard RC, et al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life patients with osteoarthritis of the knee. Arthritis Rheum. 1997;40:588.
   Google Scholar
• Geis GS, Hubbard RC, Callison D, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:S364.
   Google Scholar
• Hubbard RC, Koepp RJ, Yu S. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteo-arthritis (OA) in a short-term pilot study. Arthritis Rheum. 1996;39:5226.
   Google Scholar
• Hubbard RC, Geis GS, Woods E, et al. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum. 1998;41:5196.
   Google Scholar
• Igarashi K, Woo JT, Stem PH. Effects of a selective cyclo-oxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastgenesis in vitro. Biochem Pharmacol. 2002;63: 523–32.
   Google Scholar
• Im GI, Kwon BC, Lee KB. The effect of COX-2 inhibitors on periprosthetic osteolysis. Biomaterials. 2004;25: 269–75.
   Google Scholar
• Ono K, Akatsu T, Murakami T, et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res. 2002;17:774–81.
   PubMed Web of Science ®Google Scholar
• Zhang X, Morham SG, Langenbach R, et al. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced oste-olysis. J Bone Miner Res. 2001;16:660–70.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Nampe A, Matsui Y, et al. Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis. Mod Rheumatol. 2007;17:115–22.
   PubMedGoogle Scholar
• Okada Y, Pilbeam C, Raisz L, et al. Role of cyclooxygenase-2 in bone resorption. J UOEH. 2003;25:185–95.
   PubMedGoogle Scholar
• Fujikawa Y, Quinn JM, Sabokbar A, et al. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 1996;137:4058–60.
   PubMed Web of Science ®Google Scholar
• Taira H, Fujikawa Y, Kudo 0, et al. Menatetrenone (vitamin K2) acts directly on circulating human osteoclast precursors. Calcif Tissue Int. 2003;73: 78–85.
   Google Scholar
• Takita C, Fujikawa Y, Itonaga I, et al. Infliximab acts directly on human osteoclast precursors and enhances osteoclast formation induced by receptor activator of nuclear factor kappaB ligand in vitro. Mod Rheumatol. 2005;15:97–103.
   PubMedGoogle Scholar
• Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast dif-ferentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 1998;246:199–204.
   PubMed Web of Science ®Google Scholar
• Quinn JN, Elliott J, Gilliespie MT, et al. A combination of osteoclast differentiating factor and macrophage-colony stimu-lating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 1998;139:4424–7.
   PubMed Web of Science ®Google Scholar
• Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacoki-netics and pharmacodynamics of celecoxib. Clin Pharmacokinet. 2000;38:225–42.
   PubMed Web of Science ®Google Scholar
• Han SY, Lee NK, Kim KH, et al. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood. 2005;15:1240–5.
   Web of Science ®Google Scholar
• Fu JY, Masferrer JL, Seibert K, et al. The induction and sup-pression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737–40.
   PubMed Web of Science ®Google Scholar
• Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Nail Acad Sci USA. 1992;89:7384–8.
   PubMed Web of Science ®Google Scholar
• Stamp L, James MJ, Cleland LG. Paracrine upregulation of monocyte cyclooxygenase-2 by mediators produced by T lym-phocytes: role of interleukin 17 and interferon-y. J Rheumatol. 2004;31: 1246–54.
   Google Scholar
• Inoue Y, Otsuka T, Niiro H, et al. Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IL-10 in human monocytes. J Immunol. 2004;172:2147–54.
   PubMed Web of Science ®Google Scholar
• Ono K, Akatsu T, Kugai N, et al. The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone. 2003;33:798–804.
   PubMed Web of Science ®Google Scholar